Crouzon Syndrome - 4 Studies Found
| Terminated |
: Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) : Medical Oncology : 2015-02-16 : Drug: BAY1187982 A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the start |
| Active, not recruiting |
: Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations : Solid Tumor : 2012-12-14 : Drug: ARQ 087 Subjects in this study will receive ARQ 087 orally at dose levels specified for their resp |
| Completed |
: Dovitinib for Gastric Cancer With FGFR2 Amplification : Gastric Cancer : 2012-10-22 : Drug: Dovitinib
|
| Not yet recruiting |
: Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer :
|